StoryTest
Cambrian Bio reports Phase 1b ATX-304 results at ADA 2026: significant gains in liver fat, visceral fat and resting metabolism
At the American Diabetes Association's 86th Scientific Sessions, Cambrian Bio reported Phase 1b results for ATX-304, an AMPK activator from the Amplifier Therapeutics platform. In adults with obesity and prediabetes, ATX-304 achieved statistically significant improvements in liver fat, visceral adipose tissue, triglycerides and adiponectin, along with an 8% increase in resting metabolic rate, with tolerability comparable to placebo. Phase 2 studies were planned to begin.